Clinical Trial Update: A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of TQB2102 for injection in gynecologic cancer is currently recruiting for patients with recurrent/metastatic advanced disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Gynecological Tumors | Phase 2 | Status: RECRUITING